Table 3.
High dose EPC | Low dose EPC | OPC | Placebo | |
---|---|---|---|---|
(+) Catechin | 0.0 | 0.0 | 0.0 | 0.0 |
(‒)‐Epicatechin | 0.0 | 0.0 | 0.0 | 0.0 |
(Epi)catechin‐di‐glucuronide | 0.0 | 0.0 | 0.0 | 0.0 |
Methyl (epi)catechin | 0.0 | 0.0 | 0.0 | 0.0 |
Methyl (epi)catechin‐sulfate | 0.0 | 0.0 | 0.0 | 0.0 |
(Epi)catechin‐sulfate | 110.5 (44.8–170.8) | 53.7 (15.3–95.2) | 2.0 (0.8–3.1) | 0.3 (0.1–1.0) |
(Epi)catechin‐methyl‐sulfate | 74.6 (44.9–129.8) | 36.9 (24.7–63.0) | 1.4 (0.6–2.1) | 0.5 (0.1–1.2) |
(Epi)catechin glucuronide | 45.8 (29.3–77.8) | 19.2 (10.2–35.1) | 0.1 (0.1–0.4) | 0.1 (0.0–0.2) |
(Epi)catechin‐sulfate‐glucuronide | 13.8 (7.2–23.6) | 4.0 (3.0–9.4) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) |
(Epi)catechin‐di‐sulfate | 0.57 (0.2–1.5) | 0.7 (0.2–1.5) | 0.0 | 0.0 |
Median of (epi)catechin metabolites | 267.2 (147.8–405.9) | 109.3 (61.3–213.3) | 3.6 (1.8–5.7) | 1.0 (0.3–3.2) |
3,4DHVL 3′‐ sulfate | 38.4 (20.1–74.8) | 25.1 (13.9–62.5) | 5.2 (1.7–16.3) | 1.3 (0.3–4.4) |
3,4DHVL 4′‐glucuronide | 16.0. (7.9–32.1) | 7.6 (3.1–20.8) | 1.2 (0.4–3.6) | 0.3 (0.1–1.0) |
3,4DHVL 3′‐glucuronide | 36.0 (14.9–56.3) | 14.4 (6.4–35.1) | 2.0 (0.8–3.4) | 0.3 (0.1–1.5) |
3,4DHVL | 0.6 (0.3–1.1) | 0.4 (0.2–0.6) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) |
4H3MVL | 0.0 | 0.0 | 0.0 | 0.0 |
Median of HGVL metabolites | 99.9 (53.9–153.3) | 59.1 (26.3–146.9) | 10.8(3.1–26.9) | 2.2 (0.5–6.7) |
Data are expressed as median (upper quartile and lower quartile) in µmols 24 h−1 (n = 40 participants for high dose EPC and 42 participants for low dose EPC and OPC treatments and placebo). High and low dose EPC = 140/70 mg monomeric catechins + 130/65 mg PC, respectively; OPC = 6.5 mg monomeric catechins + 130 mg PC. 3,4DHVL = 5‐(3’,4’‐dihydroxyphenyl)‐γ‐valerolactone; ‐4H3MVL = 5‐(4‐hydroxy‐3‐methoxyphenyl)‐γ‐valerolactone